Home/ Stocks/ ABOS

Acumen Pharmaceuticals, Inc. Common Stock

ABOS XNAS

$2.44 +0.16 (+7.02%) ▲ 15-min delayed

Open

$2.29

High

$2.44

Low

$2.29

Volume

256.3K

Market Cap

$164.68M

About Acumen Pharmaceuticals, Inc. Common Stock

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 61 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-20,737,000	$-0.33
FY 2025	$0	$-121,335,000	$-2.00
Q3 2025	$0	$-26,451,000	$-0.44
Q2 2025	$0	$-40,950,000	$-0.68

Related Market News

No specific coverage for ABOS yet. Check out our latest market news or earnings calendar.

Get ABOS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Acumen Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.